Authors
Alena Roßkamp, Jacqueline Vieira, Shawkat Hussain, Julia Talarek, Faith Vinluan, Carina C D Joe, Steffi Scholze, Moritz Speckenbach, Paul Madarasi-Pap, Sophia Kueppers, Julia Niemann, Alexander D Douglas
Published in
Biotechnology and bioengineering. Nov 18, 2026. Epub Nov 18, 2026.
Abstract
Adenovirus vectors are a major vaccine platform and have potential roles as oncolytics and gene therapies. Large-scale production of adenovirus-vectored COVID-19 vaccines demonstrated the value of platform manufacturing processes for such products but vaccine scarcity remained problematic in 2021. There is a need for widely-accessible and higher-yielding platform processes for adenovirus production. Such processes must overcome cell-density-associated productivity limitation and the potential impact of vector transgene expression. We report a process capable of upstream productivity of 3 ×1012 virus particles per mL, solely using commercially-accessible materials. This combines perfusion cell culture with a highly-productive cell line capable of vector transgene repression. Using a multi-parallel scaledown perfusion bioreactor system, we selected straightforward perfusion conditions for both expansion of uninfected cells and virus production. This achieves maintenance of high cell-specific productivity at cell densities up to 40 ×106 cells per mL. We believe this may be the highest productivity yet reported for an adenovirus platform, including previous reports using proprietary cell lines. This highly productive process could be valuable both in large-scale production and in maximizing the output of smaller facilities making products for niche indications or stockpiles.
PMID:
43049530
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0